SCHEMBL24929586

SCHEMBL24929586

OC1CCN(c2ccncn2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.47
SORD Q00796 1/20 0.47
DPP4 P27487 2/20 0.45
DPP9 Q86TI2 2/20 0.45
CYP2D6 P10635 1/20 0.45
KCNH2 Q12809 1/20 0.45
DPP8 Q6V1X1 1/20 0.45
GRM1 Q13255 1/20 0.44
RIPK1 Q13546 1/20 0.43
GPBAR1 Q8TDU6 1/20 0.42
CCNC P24863 1/20 0.42
CDK8 P49336 1/20 0.42
LSS P48449 1/20 0.41
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
JAK3 P52333 1/20 0.40
PDE10A Q9Y233 2/20 0.40
MAPT P10636 1/20 0.39
PRKDC P78527 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775219 1.00 GPR119 (0.47) GPR119SORDDPP4DPP9CYP2D6
SCHEMBL30775215 1.00 GPR119 (0.47) GPR119SORDDPP4DPP9CYP2D6
SCHEMBL30775370 1.00 GPR119 (0.47) GPR119SORDDPP4DPP9CYP2D6
SCHEMBL29699634 0.90 SORD (0.53) GPR119SORDDPP4DPP9CYP2D6
SCHEMBL17208274 0.90 SORD (0.53) GPR119SORDDPP4DPP9CYP2D6
SCHEMBL29995236 0.83 SORD (0.45) GPR119SORDDPP4DPP9CYP2D6
SCHEMBL18239360 0.80 HRH4 (0.54) GPR119SORDDPP4DPP9CYP2D6
SCHEMBL674099 0.80 HRH4 (0.54) GPR119SORDDPP4DPP9CYP2D6
SCHEMBL23875356 0.80 GPR119 (0.44) GPR119SORDDPP4DPP9CYP2D6
SCHEMBL13703145 0.80 GRM1 (0.47) GPR119SORDDPP4DPP9CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190831-A1 TRANSTHYRETIN STABILIZING COMPOUNDS PROTEGO BIOPHARMA, INC. 2024-06-13 US disclosed
WO-2023009585-A2 TRANSTHYRETIN STABILIZING COMPOUNDS PROTEGO BIOPHARMA, INC. (US) 2023-02-02 WO disclosed
WO-2023009585-A2 TRANSTHYRETIN STABILIZING COMPOUNDS PROTEGO BIOPHARMA, INC. (US) 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190831-A1 TRANSTHYRETIN STABILIZING COMPOUNDS TTR, TTPA, MTPN GPR119 3856/4885SORD 752/4885DPP4 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.